Annual changes to the NASDAQ Biotechnology Index
Last week Nasdaq announced the results of the annual re-ranking of the NASDAQ Biotechnology Index, which
went into effect prior to today's market open.
The following 21 securities have been added to the Index:
Exchange
SYMBOL
COMPANY NAME
Nasdaq
AIMT
Aimmune Therapeutics, Inc.
Nasdaq
ARLZ
Aralez Pharmaceuticals Inc.
Nasdaq
AVXS
AveXis, Inc.
Nasdaq
BGNE
BeiGene, Ltd.
Nasdaq
BOLD
Audentes Therapeutics
Nasdaq
CLCD
CoLucid Pharmaceuticals
Nasdaq
CLSD
Clearside Biomedical, Inc.
Nasdaq
CYTK
Cytokinetics, Incorporated
Nasdaq
EDIT
Editas Medicine, Inc.
Nasdaq
GBT
Global Blood Therapeutics
Nasdaq
ITCI
Intra-Cellular Therapies
Nasdaq
LOXO
Loxo Oncology, Inc.
Nasdaq
MNOV
Medicinova Inc
Nasdaq
NERV
Minerva Neurosciences
Nasdaq
NH
NantHealth, Inc.
Nasdaq
NTLA
Intellia Therapeutics, Inc.
Nasdaq
NVCR
NovoCure Limited
Nasdaq
ONVO
Organovo Holdings Inc
Nasdaq
OPK
OPKO Health, Inc.
Nasdaq
PRTK
Paratek Pharmaceuticals, Inc.
Nasdaq
RGNX
REGENXBIO Inc.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 37 securities will be removed from the Index:
Exchange
SYMBOL
COMPANY NAME
Nasdaq
ADHD
Alcobra Ltd.
Nasdaq
ADVM
Adverum Biotechnologies, Inc.
Nasdaq
AFMD
Affimed N.V.
Nasdaq
AGTC
Applied Genetic Technologies Corporation
Nasdaq
ANTH
Anthera Pharmaceuticals, Inc.
Nasdaq
CARA
Cara Therapeutics, Inc.
Nasdaq
CASC
Cascadian Therapeutics, Inc.
Nasdaq
CHMA
Chiasma, Inc.
Nasdaq
CMRX
Chimerix, Inc.
Nasdaq
CNCE
Concert Pharmaceuticals, Inc.
Nasdaq
CXRX
Concordia International Corp.
Nasdaq
DNAI
ProNAi Therapeutics, Inc.
Nasdaq
DRNA
Dicerna Pharmaceuticals, Inc.
Nasdaq
DRRX
DURECT Corporation
Nasdaq
ECYT
Endocyte, Inc.
Nasdaq
EGLT
Egalet Corporation
Nasdaq
FLKS
Flex Pharma, Inc.
Nasdaq
IMDZ
Immune Design Corp.
Nasdaq
IMGN
ImmunoGen, Inc.
Nasdaq
INFI
Infinity Pharmaceuticals, Inc.
Nasdaq
ITEK
Inotek Pharmaceuticals Corporation
Nasdaq
KMPH
KemPharm, Inc.
Nasdaq
LIFE
aTyr Pharma, Inc.
Nasdaq
MNKD
MannKind Corporation
Nasdaq
NDRM
NeuroDerm Ltd.
Nasdaq
NEOS
Neos Therapeutics, Inc.
Nasdaq
OCUL
Ocular Therapeutix, Inc.
Nasdaq
OREX
Orexigen Therapeutics, Inc.
Nasdaq
OSIR
Osiris Therapeutics, Inc.
Nasdaq
OVAS
OvaScience Inc.
Nasdaq
QURE
uniQure N.V.
Nasdaq
RGLS
Regulus Therapeutics Inc.
Nasdaq
SCLN
SciClone Pharmaceuticals, Inc.
Nasdaq
TKAI
Tokai Pharmaceuticals, Inc.
Nasdaq
TTPH
Tetraphase Pharmaceuticals, Inc.
Nasdaq
VTL
Vital Therapies, Inc.
Nasdaq
ZFGN
Zafgen, Inc.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Subcutaneous Infliximab CT-P13 Superior to Placebo as Maintenance Therapy for IBD
November 16th 2024In 2 randomized controlled trials of maintenance therapy for inflammatory bowel disease (IBD), the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to placebo in patients with Crohn disease and ulcerative colitis.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.